"Serotonin Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons.
| Descriptor ID |
D018490
|
| MeSH Number(s) |
D27.505.519.625.850 D27.505.696.577.850
|
| Concept/Terms |
Serotonin Agents- Serotonin Agents
- Agents, Serotonin
- Serotonergic Drugs
- Drugs, Serotonergic
- Serotonin Drugs
- Drugs, Serotonin
- Serotonergic Agents
- Agents, Serotonergic
Serotonin Effect- Serotonin Effect
- Effect, Serotonin
- Serotoninergic Effect
- Effect, Serotoninergic
- Serotoninergic Effects
- Effects, Serotoninergic
- Serotonin Effects
- Effects, Serotonin
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Agents".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Agents".
This graph shows the total number of publications written about "Serotonin Agents" by people in this website by year, and whether "Serotonin Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin Agents" by people in Profiles.
-
Gai/o-coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents. Cell Rep. 2021 11 16; 37(7):109997.
-
Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020 05; 127(5):843-850.
-
Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2017 Feb; 37(1):46-53.
-
Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist. PLoS One. 2016; 11(7):e0159776.
-
Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics. 2015; 16(11):1307-14.
-
Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012 Dec; 9(12):3180-8.
-
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012 Mar; 9(3):793-804.
-
Psychotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep. 2009 Aug; 11(4):296-301.
-
Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry. 2009 Jan 15; 65(2):150-9.
-
3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus. Neuroscience. 2008 Jul 31; 155(1):270-6.